enGene Therapeutics Inc.
Biological Products, (No Diagnostic Substances) | SIC: 2836Phone: (514) 332-4888
State of Inc.: Z4
- Nasdaq:ENGN
- Nasdaq:ENGNW
Form: 10-K/A
Filing Date: 19 Feb 2026Report Date: 31 Oct 2025
Accepted: 19 Feb 2026 02:15 p.m.
Accession Number: 0001193125-26-059409
File Number: 001-41854
Film Number: 26654587
Documents
Primary Document: 10-K/A
Accepted: 19 Feb 2026 02:15 p.m.
0001193125-26-059409-index-headers.html
Last Modified: 19 Feb 2026 02:15 p.m.
0001193125-26-059409-index.html
Last Modified: 19 Feb 2026 02:15 p.m.
0001193125-26-059409.txt
Last Modified: 19 Feb 2026 02:15 p.m.
0001193125-26-059409-xbrl.zip
Last Modified: 19 Feb 2026 02:15 p.m.
engn-20251031.xsd
Last Modified: 19 Feb 2026 02:15 p.m.
engn-20251031_htm.xml
Last Modified: 19 Feb 2026 02:15 p.m.
engn-ex31_3.htm
Last Modified: 19 Feb 2026 02:15 p.m.
engn-ex31_4.htm
Last Modified: 19 Feb 2026 02:15 p.m.
FilingSummary.xml
Last Modified: 19 Feb 2026 02:15 p.m.
MetaLinks.json
Last Modified: 19 Feb 2026 02:15 p.m.
R1.htm
Last Modified: 19 Feb 2026 02:15 p.m.
R2.htm
Last Modified: 19 Feb 2026 02:15 p.m.
report.css
Last Modified: 19 Feb 2026 02:15 p.m.
Show.js
Last Modified: 19 Feb 2026 02:15 p.m.